Objective
The objective of the study was to generate the market access insights with respect to following points
- Understanding current treatment patterns, identifying drivers &barriers, and unmet needs for product X
- Rating on product X attributes (Indications, Efficacy, Safety, Administration and Dosing, Mode of Action, Therapeutic Benefits, and Price)
- Factors affecting status of Pricing & Reimbursement
- Price point for product X, willing -to-pay price cap, and reasons of price cap/ % of the product price will be reimbursed/ co-pay
- Potential market for product X; Estimated Patient pool by indication types
- Market projections-2021 to 2030
Approach
eQuantX referred to a wide variety of proprietary and secondary sources to capture and validate the information nuggets
A detailed discussion has been planned with the leading payers (Insurance Providers) in US: UnitedHealth, Anthem, Kaiser Foundation, Centene Corp, Humana, Cigna Health, HCSC, CVS, Molina Healthcare, Aetna etc. and PBM, also with the govt. payers: Medicare, Medicaid, Managed Care Organizations, TPAs and Government Agencies including Other Federal Payers i.e. GEHA/ VA across US regions, who are responsible for processing patient eligibility, enrollment, claims, payment and make informed, evidence-based decisions on which treatments to fund
Outcome
The output of the research helps client in assessing payer’s initial reaction to product X, identifying potential pricing and reimbursement scenarios for product X, and further recognizing drivers to product X, HSCT cost break-up, coverage and current reimbursement structure
The research findings support client in understanding the top unmet needs in HSCT patients, the potential market for product-X and provided the clear understanding on the potential ‘Pricing vs. Market Share’ which helped client in formulating ‘Pricing Strategy for product X’
